Vagizole Gel
NDC Package 87687-002-70

11-digit billing NDC: 87687000270

Package Information

Vagizole (metronidazole) gel is metronidazole vaginal gel is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilusvaginitis, Gardnerellavaginitis, nonspecific vaginitis, Corynebacteriumvaginitis, or anaerobic vaginosis). This formulation utilizes a gel delivery system. Marketed by Inutrition Llc, this product is identified by NDC 87687-002 and is authorized under FDA application ANDA213648.

Identification & Billing

NDC Package Code
87687-002-70
Package Description
1 TUBE, WITH APPLICATOR in 1 CARTON / 70 g in 1 TUBE, WITH APPLICATOR
Product Code
11-Digit Billing Format
87687000270
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Vagizole
Non-Proprietary Name
Metronidazole
Substance Name
Metronidazole
Dosage Form
Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.
Administration Route
Vaginal - Administration into the vagina.
Active Ingredient(s)
Usage Information
Metronidazole vaginal gel is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilusvaginitis, Gardnerellavaginitis, nonspecific vaginitis, Corynebacteriumvaginitis, or anaerobic vaginosis). NOTE:For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillusmorphology, (b) predominance of Gardnerellamorphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans,and Herpes simplexvirus should be ruled out.

Regulatory & Marketing

Labeler Name
Inutrition Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA213648
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-29-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 87687-002-70 identifies a specific commercial package of 1 tube, with applicator in 1 carton / 70 g in 1 tube, with applicator of Vagizole, a human prescription drug labeled by Inutrition Llc. This gel is formulated for vaginal use and contains metronidazole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Inutrition Llc on June 29, 2026. The current certification is valid through December 31, 2027.

How is this Inutrition Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 87687000270. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
87687-002-70
11-Digit CMS (5-4-2)
87687-0002-70

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.